Dupilumab‐related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London
Abstract Background Dupilumab is the first human monoclonal antibody approved for the treatment of moderate–severe atopic dermatitis (AD) in children from 6 years of age. Real‐world studies reviewing dupilumab‐related ocular surface disorders (DROSD) in the paediatric population are needed to detail...
में बचाया:
| मुख्य लेखकों: | , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Wiley
2024-12-01
|
| श्रृंखला: | JEADV Clinical Practice |
| विषय: | |
| ऑनलाइन पहुंच: | https://doi.org/10.1002/jvc2.528 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|